NCT07644897招募中2 期
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Sun Yat-sen University2 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2023年5月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
- 试验地点
- 2
- 主要终点
- Objective Response Rate
研究概览
简要总结
Primary Objective:
To evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma .
Secondary Objective:
To evaluate the safety and tolerability of adenpeptide-α1 combined with PD-1 antibody in elderly patients with advanced melanoma .
Study Design：Open-label, single-arm, non-controlled clinical trial.
Primary Inclusion Criteria:
- Age ≥60 years old;
- Pathologically confirmed as inoperable or metastatic melanoma;
- one or more lesions evaluable by RECIST1.1 standards.
- The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States scores from 0-2;
Main exclusion criteria:
- Received treatment with a regimen containing PD-1, PD-L1, or CTLA-4 antibodies within the past 6 months;
- Received thymosin class drug treatment within 3 months before signing the informed consent.
- Symptomatic, untreated central nervous system metastases. Treatment： Thymosin Alpha 1 1.6mg, sc，QD，d1-7;1.6mg, sc， three times per week, d8-21. Each 21 days is considered one cycle, for a total of 12 weeks.
Anti-PD-1 monoclonal antibody (Toripalimab) 240mg per dose,ivdrip，Q3W，4 cycles.
Primary study endpoints:
Objective Response Rate (ORR: CR+PR)
Secondary study endpoints:
Progression-Free Survival (PFS), Duration of Response (DOR), Overall Survival (OS) Adverse Events (AEs)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 60 years or older;
- •Diagnosis of malignant melanoma confirmed by pathological histology or cytology examination.
- •According to the 8th edition of AJCC staging, patients with unresectable stage III or IV melanoma;
- •One or more lesions evaluable by RECIST1.1 standards.
- •The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States has a score range of 0-
- •Total bilirubin ≤1.5× upper limit of normal (ULN); AST and AST <2.5× upper limit of normal (ULN).(No liver metastasis), or <5 times the upper limit of normal (ULN) (with liver metastasis);
- •Patients with recurrent metastasis who have not previously received immunotherapy such as PD-1, PD-L1, CTLA-4 antibodies，also allowed for the enrollment of patients who had used adjuvant/neoadjuvant therapies
- •If the adjuvant or neoadjuvant treatment plan includes PD(L)-1 or CTLA-4 monoclonal antibodies, it is required that only those who progress more than 6 months after the end of the treatment plan can be included in the study group.
- •If the adjuvant or neo-adjuvant treatment plan does not include PD(L)-1 or CTLA-4 monoclonal antibodies, patients who progress during the adjuvant treatment are allowed to participate in the study.
- •Has signed the informed consent form, able to comply with the study protocol and follow-up plan.
排除标准
- •Received treatment involving PD-1, PD-L1, or CTLA-4 antibody regimen within the past 6 months;
- •Patients who have received treatment with thymosin, thymopentin, or thymosin a-1d within 3 months prior to enrollment.
- •Presence of symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. For subjects with previously treated CNS metastases, if the subject's condition is stable (no evidence of radiographic progression for at least weeks prior to the first administration of the study intervention, and all neurological symptoms have returned to baseline), repeat radiographic examination confirms no evidence of new brain metastases or enlargement of existing brain metastases, and no need for steroid treatment for at least 14 days prior to the first administration of the study intervention, they may participate in the study.
- •Patients with active systemic autoimmune diseases requiring systemic treatment (i.e., using immunomodulators, corticosteroids, or immunosuppressants). Replacement therapies (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered systemic treatment.
- •Has a history of immunodeficiency, including testing positive for HIV, or suffering from other acquired or congenital immunodeficiency diseases, or has a history of organ transplantation and bone marrow transplantation.
- •6）Allergic to the investigational drug or its components; 7）Presence of active infection requiring systemic treatment; 8) Uncontrolled internal medical complications, such as unstable congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accidents, and hemodynamically unstable arrhythmias, etc.
- •9) The investigator deems them unsuitable for inclusion.
研究组 & 干预措施
intervention group
Experimental
Thymosin Alpha 1 and anti-PD-1 monoclonal antibody
干预措施: Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: up to 24 weeks
defined as the best overall response of complete remission or partial remission,
次要结局
- Progression-Free Survival (PFS)(Assessed until 12 months after the first dose of the last enrolled patient, estimated up to 5 years.)
- overall survival (OS)(Assessed until 12 months after the first dose of the last enrolled patient, estimated up to 5 years.)
- Adverse Events (AEs)(Assessed until 12 months after the first dose of the last enrolled patient, estimated up to 5 years.)
- Duration of Response (DOR),(Assessed until 12 months after the first dose of the last enrolled patient, estimated up to 5 years.)
研究者
xizhi wen
Principal investigator
Sun Yat-sen University
研究点 (2)
Loading locations...
相似试验
尚未招募
2 期
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Colorectal NeoplasmsProstatic NeoplasmsCholangiocarcinomaUterine Cervical NeoplasmsTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and NeckEsophageal Squamous Cell CarcinomaGallbladder NeoplasmsPancreatic Ductal AdenocarcinomaCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaNCT07623642GV20 Therapeutics227
招募中
2 期
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)NCT07410520The First Affiliated Hospital with Nanjing Medical University50
已完成
不适用
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line TreatmentHepatocellulcar CarcinomaNCT07537985Sun Yat-sen University200
招募中
2 期
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaNasopharyngeal Cancinoma (NPC)NCT07528183Sun Yat-sen University62
招募中
2 期
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPCNasopharangeal CancerRecurrent Nasopharynx CarcinomaNCT07332247Sun Yat-sen University94